FOXM1 and prostate carcinoma: AKT can control FOXM1 expression in osteosarcoma [21], and the downregulation of AKT by siRNA has been shown to inhibit FOXM1 expression, whereas the overexpression of AKT has been shown to increase FOXM1 expression in prostate cancer [15]; however, its role in melanoma cells has not been reported.